Wayne interview with The Market Herald, page-3

Hi synaphai , I tend to agree with Eire when it comes down to the end game of AVRs future . Yes AVR could possibly take the DurAVR to completion but WP would be well aware of the issues he could possibly face with the FDA and if AVR had to market and distribute the DurAVR themselves . I have held shares over the years with many Aust companies seeking FDA approval or trials. IMO not one has received what I believe to be equal treatment by comparison to what a US based company would encounter doing exactly the same thing . As I have stated many times here my belief is the ADAPT platform and IP utilised in the DurAVR is worth significantly more than investors are currently placing on it . It would not surprise me to see AVR pull out a few new products and possibly trialing them that utilise this technology over the next 12 mths . IMO AVR will probably be acquired with 1 or possibly 2 or. 3 projects well underway . If infact this eventuates AVR will be in the box seat when it comes down to any ( I believe many ) aquisition offers that will be made . I do think AVR will get its products into trials but the FDA just appears to put road blocks up in front of non US companies. WP is a smart operator as is well aware of these issues no doubt. GLTATH